Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps—Are We Comparing Apples With Oranges?

International Forum of Allergy & Rhinology 2026 Open access

Read full text
Authors: Marjolein Cornet, Peter W. Hellings, Martin Desrosiers, Martin Wagenmann, Richard Follows, Laura Walgrave, Luz Adriana Jimenez, Lee Tombs, Dawn Edwards, Peter Howarth, J K Han
DOI: 10.1002/alr.70205
Cited by: 1
References: 30

Abstract

KEY POINTS: In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data-handling processes. While (in)direct treatment comparisons and meta-analyses have been carried out to compare efficacy results from RCTs, often these fail to properly account for these between-study differences. Here, we summarize the key between-study differences that can influence trial outcomes and highlight the resulting challenges faced when comparing outcomes from different Phase III RCTs of biologics in CRSwNP.

Fields of Study & Subjects

Sinusitis and nasal conditions Allergic Rhinitis and Sensitization Nasal Surgery and Airway Studies

Publication details

Journal / source
International Forum of Allergy & Rhinology
Publisher
Wiley
Volume
16
Issue
8
Pages
769–777
Publication date
3 July 2026
Language
EN